Hospital
Lifebrite Hospital Group of Stokes, LLC
Lifebrite Hospital Group of Stokes, LLC was paid $1.32M by Medicaid between Jan 2018 and Nov 2024, across 70 billing codes. Its largest line is 99283, emergency room visit (moderate) — 46% of everything it billed.
33Billing provider infoLIFEBRITE HOSPITAL GROUP OF STOKES, LLC
DANBURY, NC 27016
DANBURY, NC 27016
33aNPI1396288999assigned 11/30/2016
33bProvider typeCritical Access Hospital
28Total paid$1.32M
24GClaims24,719
24DCodes billed70
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Critical Access Hospital providers in North Carolina
Rank by total paid#13 of 25
Median peer was paid$1.32M
This provider vs. median1.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 10,104 | $484K | |
| 2019 | 6,519 | $277K | |
| 2020 | 1,844 | $60K | |
| 2021 | 1,676 | $72K | |
| 2022 | 1,577 | $145K | |
| 2023 | 1,946 | $171K | |
| 2024incomplete | 1,053 | $116K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 46% | 3,001 | 2,592 | $615K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 17% | 1,577 | 1,390 | $229K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 14% | 712 | 585 | $179K |
| 87428 | 2.0% | 463 | 427 | $26K | |
| 71046 | Radiologic examination, chest; 2 views | 1.8% | 326 | 277 | $24K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.5% | 474 | 331 | $20K |
| 80363 | 1.2% | 171 | 127 | $15K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 908 | 521 | $13K |
| 80053 | Comprehensive metabolic panel | <1% | 1,988 | 1,662 | $12K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 256 | 201 | $12K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 875 | 803 | $11K |
| 80347 | <1% | 170 | 126 | $10K |
58 more codes
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 1,761 | $10K |
| 80337 | <1% | 150 | $7K | |
| J3490 | Unclassified drugs | <1% | 2,684 | $7K |
| 80351 | <1% | 151 | $7K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 522 | $7K |
| 80321 | <1% | 142 | $7K | |
| 87081 | <1% | 1,046 | $6K | |
| 80370 | <1% | 171 | $6K | |
| 80373 | <1% | 171 | $6K | |
| 80368 | <1% | 164 | $6K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 225 | $5K |
| 80367 | <1% | 171 | $5K | |
| 80356 | <1% | 157 | $5K | |
| 80359 | <1% | 153 | $5K | |
| 80366 | <1% | 154 | $5K | |
| 80348 | <1% | 171 | $5K | |
| 80357 | <1% | 144 | $4K | |
| 80372 | <1% | 170 | $4K | |
| 80358 | <1% | 173 | $4K | |
| 80355 | <1% | 154 | $4K | |
| 80324 | <1% | 170 | $4K | |
| 80345 | <1% | 171 | $4K | |
| 80353 | <1% | 170 | $4K | |
| 80349 | <1% | 126 | $3K | |
| 80061 | Lipid panel | <1% | 216 | $3K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 69 | $2K |
| 99285 | Emergency room visit (most serious) | <1% | 14 | $2K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 182 | $2K |
| 83986 | <1% | 171 | $1K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 61 | $1K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 60 | $1K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 94 | $1K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 158 | $1K |
| 81003 | <1% | 235 | $1K | |
| 71045 | Radiologic examination, chest; single view | <1% | 31 | $1K |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,013 | $940.41 |
| 73630 | <1% | 16 | $934.90 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 49 | $757.06 |
| 81001 | <1% | 278 | $534.51 | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 22 | $517.75 |
| 81025 | <1% | 84 | $511.34 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 32 | $448.89 |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 93 | $440.37 |
| 83735 | <1% | 167 | $429.64 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 65 | $288.88 |
| 83874 | <1% | 64 | $252.11 | |
| A9150 | Non-prescription drugs | <1% | 860 | $247.05 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 72 | $228.93 |
| 82553 | <1% | 63 | $225.65 | |
| 80305 | <1% | 25 | $207.87 | |
| 84484 | <1% | 68 | $196.41 | |
| 97161 | <1% | 12 | $178.72 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 12 | $126.86 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 71 | $104.47 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 29 | $79.60 |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 117 | $49.68 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 12 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFLETCHER, CHRISTIAN (CEO)
| Provider | Location | Paid |
|---|---|---|
| Lifebrite Laboratories, LLC | Brookhaven, GA | $9.38M |
| United Physician Group LLC | Brookhaven, GA | $1.94M |
| Lifebrite Hospital Group of Stokes, LLC | Danbury, NC | $1.08M |
| Lifebrite Hospital Group of Stokes, LLC | Danbury, NC | $647K |
| Lifebrite Hospital Group of Stokes, LLC | Danbury, NC | $171K |
| Lifebrite Hospital Group of Stokes, LLC | King, NC | $20K |
| Lifebrite Hospital Group of Stokes, LLC | Danbury, NC | $16K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.